3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Radiotherapy
3
Propranolol
3
Cisplatin
3
entecavir
2
Tranexamic Acid
2
Pemetrexed
2
Metformin
2
Erythromycin
2
Epinephrine
2
Cyclophosphamide
2
Chemoradiotherapy
2
Bortezomib
2
ulipristal acetate
1
tislelizumab
1
plerixafor
1
lobaplatin
1
ledipasvir
1
eribulin
1
endostar protein
1
dolutegravir
1
colistinmethanesulfonic acid
1
cetrorelix
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
XELOX
1
Vancomycin
1
Vacuum Curettage
1
Vaccination
1
Suction
1
Sofosbuvir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
OTHER_GOV
×
Nucleosides
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn